Payment overview · 2025
General Payments
$27.59
2 reported records · 2 companies
Healthcare provider profile · identity verified
Deepak Nayyar, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · CASA GRANDE, AZ · NPI 1790900827
Verified facts
What the public records show
CMS Open Payments records show Deepak Nayyar, M.D. received $27.59 in general payments during 2025 across 2 reported records.
GlaxoSmithKline, LLC. accounted for 50.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 3 associated products.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $14.05 | 50.9% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $13.54 | 49.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $27.59 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $14.05 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $13.54 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $13.54 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
No publishable same-company prescribing overlap was found in the loaded Part D year. This does not mean the doctor never prescribed a drug reported elsewhere by a paying company.
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1031 | 326 |
| Lisinopril | Lisinopril | 673 | 208 |
| Amlodipine Besylate | Amlodipine Besylate | 594 | 201 |
| Levothyroxine Sodium | Levothyroxine Sodium | 478 | 137 |
| Metformin Hcl | Metformin Hcl | 440 | 133 |
| Omeprazole | Omeprazole | 332 | 102 |
| Losartan Potassium | Losartan Potassium | 315 | 98 |
| Gabapentin | Gabapentin | 302 | 91 |
| Metoprolol Tartrate | Metoprolol Tartrate | 216 | 70 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 198 | 52 |
| Pioglitazone Hcl | Pioglitazone Hcl | 194 | 53 |
| Tamsulosin Hcl | Tamsulosin Hcl | 193 | 64 |
| Hydrochlorothiazide | Hydrochlorothiazide | 190 | 51 |
| Glimepiride | Glimepiride | 176 | 43 |
| Pantoprazole Sodium | Pantoprazole Sodium | 175 | 54 |
| Metoprolol Succinate | Metoprolol Succinate | 159 | 48 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 150 | 44 |
| Simvastatin | Simvastatin | 144 | 42 |
| Pravastatin Sodium | Pravastatin Sodium | 136 | 43 |
| Trazodone Hcl | Trazodone Hcl | 133 | 35 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 132 | 33 |
| Fluticasone Propionate | Fluticasone Propionate | 129 | 34 |
| Glipizide Er | Glipizide | 129 | 47 |
| Naproxen | Naproxen | 126 | 43 |
| Tizanidine Hcl | Tizanidine Hcl | 126 | 50 |
| Ibuprofen | Ibuprofen | 118 | 42 |
| Carvedilol | Carvedilol | 109 | 33 |
| Atenolol | Atenolol | 105 | 26 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 103 | 30 |
| Trulicity | Dulaglutide | 102 | 21 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 95 | 28 |
| Metformin Hcl Er | Metformin Hcl | 93 | 23 |
| Hydralazine Hcl | Hydralazine Hcl | 92 | 25 |
| Oxybutynin Chloride | Oxybutynin Chloride | 92 | 22 |
| Warfarin Sodium | Warfarin Sodium | 92 | 17 |
| Sertraline Hcl | Sertraline Hcl | 90 | 26 |
| Fenofibrate | Fenofibrate | 89 | 24 |
| Glipizide | Glipizide | 89 | 32 |
| Prednisone | Prednisone | 82 | 73 |
| Furosemide | Furosemide | 81 | 30 |
| Meloxicam | Meloxicam | 78 | 24 |
| Alendronate Sodium | Alendronate Sodium | 72 | 20 |
| Duloxetine Hcl | Duloxetine Hcl | 72 | 16 |
| Eliquis | Apixaban | 70 | 23 |
| Azithromycin | Azithromycin | 67 | 64 |
| Citalopram Hbr | Citalopram Hydrobromide | 67 | 16 |
| Jardiance | Empagliflozin | 61 | 20 |
| Potassium Chloride | Potassium Chloride | 59 | 18 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 55 | 47 |
| Clopidogrel | Clopidogrel Bisulfate | 54 | 24 |
| Doxycycline Hyclate | Doxycycline Hyclate | 52 | 42 |
| Tramadol Hcl | Tramadol Hcl | 52 | 21 |
| Allopurinol | Allopurinol | 47 | 15 |
| Baclofen | Baclofen | 46 | 11 |
| Nifedipine Er | Nifedipine | 44 | 12 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 43 | 39 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 43 | 17 |
| Lovastatin | Lovastatin | 42 | 12 |
| Montelukast Sodium | Montelukast Sodium | 41 | 12 |
| Clonidine Hcl | Clonidine Hcl | 39 | 13 |
| Famotidine | Famotidine | 39 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 38 | suppressed |
| Ozempic | Semaglutide | 37 | suppressed |
| Spironolactone | Spironolactone | 37 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 36 | suppressed |
| Cephalexin | Cephalexin | 35 | 32 |
| Propranolol Hcl | Propranolol Hcl | 35 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 34 | 13 |
| Meclizine Hcl | Meclizine Hcl | 34 | 15 |
| Buspirone Hcl | Buspirone Hcl | 32 | 13 |
| Januvia | Sitagliptin Phosphate | 32 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 30 | 16 |
| Chlorthalidone | Chlorthalidone | 28 | suppressed |
| Bumetanide | Bumetanide | 27 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 27 | 12 |
| Synthroid | Levothyroxine Sodium | 27 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 25 | suppressed |
| Finasteride | Finasteride | 25 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 24 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 24 | 12 |
| Nortriptyline Hcl | Nortriptyline Hcl | 24 | suppressed |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 24 | 11 |
| Doxazosin Mesylate | Doxazosin Mesylate | 23 | suppressed |
| Amoxicillin | Amoxicillin | 22 | 21 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 22 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 21 | suppressed |
| Linzess | Linaclotide | 21 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 21 | suppressed |
| Estradiol | Estradiol | 20 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 20 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 20 | suppressed |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 19 | 19 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 19 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Memantine Hcl | Memantine Hcl | 18 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 18 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 17 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Mounjaro | Tirzepatide | 17 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Acyclovir | Acyclovir | 16 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 16 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 16 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 16 | suppressed |
| Pregabalin | Pregabalin | 16 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 16 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 15 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 15 | suppressed |
| Celecoxib | Celecoxib | 14 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 14 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 14 | suppressed |
| Novolog Flexpen | Insulin Aspart | 14 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 14 | 13 |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Brilinta | Ticagrelor | 13 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 13 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 13 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 13 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 13 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 13 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 13 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 12 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 12 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 12 | suppressed |
| Levetiracetam | Levetiracetam | 12 | suppressed |
| Ezetimibe | Ezetimibe | 11 | suppressed |
| Humalog | Insulin Lispro | 11 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 11 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 11 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 11 | suppressed |
| Vascepa | Icosapent Ethyl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $27.59 · 2 records | GlaxoSmithKline, LLC. | EVENITY, PROLIA, SHINGRIX | — | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error